Abstract
Many recent advances in cancer therapy have been based on an understanding of the basic biology of the cancer cell itself, particularly with respect to abnormalities in various signalling pathways. It has become increasingly apparent that malignant cells exist in a complex cellular and extracellular microenvironment, which can play key roles in the initiation and maintenance of the malignant phenotype. These interactions can provide therapeutic targets that are now being exploited in the clinic. Much attention has been paid to agents that disrupt angiogenesis or existing tumor vasculature, however other cellular and non-cellular components of the tumor mass mediate critical functions and can also be useful treatment targets. Treatments directed at these interactions bring new challenges in terms of how best to develop these strategies, and require approaches that differ in many ways from conventional anticancer therapies.
Keywords: Angiogenesis, vasculature, stroma, cancer, tumor, therapy
Current Cancer Drug Targets
Title: Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Volume: 8 Issue: 6
Author(s): Ian D. Davis and Jayesh Desai
Affiliation:
Keywords: Angiogenesis, vasculature, stroma, cancer, tumor, therapy
Abstract: Many recent advances in cancer therapy have been based on an understanding of the basic biology of the cancer cell itself, particularly with respect to abnormalities in various signalling pathways. It has become increasingly apparent that malignant cells exist in a complex cellular and extracellular microenvironment, which can play key roles in the initiation and maintenance of the malignant phenotype. These interactions can provide therapeutic targets that are now being exploited in the clinic. Much attention has been paid to agents that disrupt angiogenesis or existing tumor vasculature, however other cellular and non-cellular components of the tumor mass mediate critical functions and can also be useful treatment targets. Treatments directed at these interactions bring new challenges in terms of how best to develop these strategies, and require approaches that differ in many ways from conventional anticancer therapies.
Export Options
About this article
Cite this article as:
Davis D. Ian and Desai Jayesh, Clinical Use of Therapies Targeting Tumor Vasculature and Stroma, Current Cancer Drug Targets 2008; 8 (6) . https://dx.doi.org/10.2174/156800908785699388
DOI https://dx.doi.org/10.2174/156800908785699388 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sugars and Sweeteners: Structure, Properties and In Silico Modeling
Current Medicinal Chemistry Mammalian Cell Competitions, Cell-in-Cell Phenomena and Their Biomedical Implications.
Current Molecular Medicine Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Amelioration of Cisplatin Induced Nephrotoxicity by Standardized Methanolic Extract of Roots of Boerhaavia diffusa
The Natural Products Journal Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Fluorescent Carbon Dots and Nanodiamonds for Biological Imaging: Preparation, Application, Pharmacokinetics and Toxicity
Current Drug Metabolism New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Drug Targets to Pro-Angiogenetic Factors with Special Reference to Primary Peritoneal Mesothelioma
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
Mini-Reviews in Medicinal Chemistry NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting <i>HIF1A</i> in <i>NONO-TFE3</i> Translocation Renal Cell Carcinoma
Current Cancer Drug Targets Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents
Current Medicinal Chemistry ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players
Current Medicinal Chemistry Recent Development of Copolymeric Delivery System for Anticancer Agents Based on Cyclodextrin Derivatives
Anti-Cancer Agents in Medicinal Chemistry Multiple Target-Specific Molecular Agents for Detection and Image Analysis of Breast Cancer Characteristics in Mice
Current Molecular Medicine Amyloidogenicity of p53: A Hidden Link Between Protein Misfolding and Cancer
Current Protein & Peptide Science Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry